February 8, 2021 – The second edition of Nutraceuticals: Efficacy, Safety and Toxicity by Ramesh C. Gupta has been released by Elsevier’s Academic Press, with chapters contributed by KGK Science’s leading scientists and regulatory team. The textbook is used as a resource at academic institutions for students to learn about nutraceuticals, their potential toxic effects, and the regulatory aspects of the global nutraceutical market.
Chapter 39, Cannabidiol Safety was written by KGK’s regulatory and toxicology experts Andrew Charrette, Director of Regulatory Affairs; James Akingbasote, toxicologist; Dr. Corey J. Hilmas, Chief Regulatory Officer; and Najla Guthrie, KGK President and CEO. The chapter discusses the evidence for safety and gaps in toxicology of CBD in the context of its use in conventional foods, dietary supplements, and health and wellness products. The primer provides an analysis of genotoxicity, preclinical studies, and evidence from human clinical trials, with a particular emphasis on selecting the most appropriate animal model for CBD research.
Chapter 71, The Regulatory Framework for Nutraceuticals: North America provides a comprehensive understanding of the current regulatory frameworks for nutraceutical products in Canada and the U.S. The chapter also discusses the future of nutraceuticals in North America, and the significant changes on the horizon due to illicit cannabidiol products. Co-written by regulatory professionals Andrew Charette and Dr. Corey J. Hilmas as well as KGK CEO Najla Guthrie, the work integrates KGK’s regulatory expertise, gained from 24 years supporting the nutraceutical and natural health product industries, with its experience as the leading CRO within the cannabis industry.
Nutraceuticals: Efficacy, Safety and Toxicity, Second Edition ©2021 Elsevier Inc.
Edited by Ramesh C. Gupta, Rajiv Lall, and Ajay Srivastava
Contact: Lauren Redman, Director of Marketing | (519) 438-9374 x 254 | email@example.com